Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop

Matthew R. Young, Paul D. Wagner, Sharmistha Ghosh, Jo Ann Rinaudo, Stuart G. Baker, Kenneth S. Zaret, Michael S Goggins, Sudhir Srivastava

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.

Original languageEnglish (US)
Pages (from-to)135-141
Number of pages7
JournalPancreas
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Tumor Biomarkers
Pancreatic Neoplasms
Early Detection of Cancer
Biomarkers
Education
Survival
National Cancer Institute (U.S.)
Cause of Death
Neoplasms
Sensitivity and Specificity
Research

Keywords

  • biomarkers
  • early detection
  • PDAC
  • validation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Validation of Biomarkers for Early Detection of Pancreatic Cancer : Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop. / Young, Matthew R.; Wagner, Paul D.; Ghosh, Sharmistha; Rinaudo, Jo Ann; Baker, Stuart G.; Zaret, Kenneth S.; Goggins, Michael S; Srivastava, Sudhir.

In: Pancreas, Vol. 47, No. 2, 01.02.2018, p. 135-141.

Research output: Contribution to journalArticle

Young, Matthew R. ; Wagner, Paul D. ; Ghosh, Sharmistha ; Rinaudo, Jo Ann ; Baker, Stuart G. ; Zaret, Kenneth S. ; Goggins, Michael S ; Srivastava, Sudhir. / Validation of Biomarkers for Early Detection of Pancreatic Cancer : Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop. In: Pancreas. 2018 ; Vol. 47, No. 2. pp. 135-141.
@article{4158a876f779416e93201af291bbf7d8,
title = "Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop",
abstract = "Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10{\%}. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.",
keywords = "biomarkers, early detection, PDAC, validation",
author = "Young, {Matthew R.} and Wagner, {Paul D.} and Sharmistha Ghosh and Rinaudo, {Jo Ann} and Baker, {Stuart G.} and Zaret, {Kenneth S.} and Goggins, {Michael S} and Sudhir Srivastava",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/MPA.0000000000000973",
language = "English (US)",
volume = "47",
pages = "135--141",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Validation of Biomarkers for Early Detection of Pancreatic Cancer

T2 - Summary of the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop

AU - Young, Matthew R.

AU - Wagner, Paul D.

AU - Ghosh, Sharmistha

AU - Rinaudo, Jo Ann

AU - Baker, Stuart G.

AU - Zaret, Kenneth S.

AU - Goggins, Michael S

AU - Srivastava, Sudhir

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.

AB - Pancreatic cancer is the third leading cause of cancer death in the United States, and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The National Cancer Institute in partnership with the Kenner Family Research Fund and the Pancreatic Cancer Action Network convened a Data Jamboree on Biomarkers workshop on December 5, 2016, to discuss and evaluate existing or newly developed biomarkers and imaging methods for early detection of pancreatic cancer. The primary goal of this workshop was to determine if there are any promising biomarkers for early detection of pancreatic cancer that are ready for clinical validation. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection, formed under the auspices of this workshop, will provide the common platform and the resources necessary for validation. Although none of the biomarkers evaluated seemed ready for a large-scale biomarker validation trial, a number of them had sufficiently high sensitivity and specificity to warrant additional research, especially if combined with other biomarkers to form a panel.

KW - biomarkers

KW - early detection

KW - PDAC

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=85040992686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040992686&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000973

DO - 10.1097/MPA.0000000000000973

M3 - Article

C2 - 29346214

AN - SCOPUS:85040992686

VL - 47

SP - 135

EP - 141

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -